Genprex

Reprogramming the course of cancer

Technology

Our platform technologies are designed to administer cancer fighting tumor suppressor genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities.

Pipeline

We are developing our lead product candidate, Oncoprex™ immunogene therapy, to be administered in combination with targeted therapies and immunotherapies for non-small cell lung cancer. Preclinical research indicates that Oncoprex might also be effective in fighting other types of cancer and we are exploring its use in other cancer types.

Management Team

We are a multidisciplinary team with broad business experience in the biotech and pharmaceutical industries, and research and clinical experience at preeminent medical and academic institutions around the world. Our management team pairs an unmatched expertise with a knack for innovation in research.

Learn More

About Us


At Genprex, we are committed to pioneering a new approach to treating cancer, based upon our novel proprietary technology platform, including our initial product candidate, Oncoprex™ immunogene therapy, or Oncoprex. Our platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities.

What they’re saying

In the Media


Catch up with our

Latest News


Genprex Wins FDA Fast Track Status for its Oncoprex Therapy in Combination with AstraZeneca’s Tagrisso

Genprex Inc (NASDAQ:GNPX) announced that the US Food and Drug Administration has granted Fast Track Designation for its Oncoprex immunogene therapy to treat lung cancer.

FDA Grants Fast Track Designation to Oncoprex Combination for NSCLC

Oncoprex in combination with Tagrisso received fast track designation from the Food and Drug Administration to treat patients with non-small cell lung cancer.

FDA Grants Fast Track Designation to Gene Therapy Combination in EGFR-Mutant NSCLC

The FDA has granted a Fast Track Designation to the immune-gene therapy Oncoprex in combination with the EGFR inhibitor osimertinib (Tagrisso) for the treatment of patients with EGFR-mutant non–small cell lung cancer (NSCLC) who have progressed after treatment with osimertinib alone, according to a press release from Genprex, Inc, developer of the therapeutic.

Genprex, Inc. Prices $8,000,000 Common Stock Offering Priced At-The-Market

Genprex today announced it has entered into securities purchase agreements with institutional investors for the purchase and sale of 7,620,000 shares of common stock, par value $0.001 per share at an offering price of $1.05 per share, pursuant to a registered direct offering, priced at-the-market under Nasdaq rules.